SCHEMBL90346

SCHEMBL90346

COCCN(Cc1cc(CNC2CC2)cc(OC)c1)C(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
TSHR P16473 2/20 0.45
L3MBTL1 Q9Y468 3/20 0.42
KDM4E B2RXH2 3/20 0.38
LMNA P02545 1/20 0.38
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
NCOR2 Q9Y618 1/20 0.35
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34
GRIN2B Q13224 1/20 0.34
GRIN2C Q14957 1/20 0.34
GRIN3A Q8TCU5 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
ROCK2 O75116 1/20 0.34
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL89599 0.82 GRIN2D (0.40) TSHRL3MBTL1HDAC3HDAC1HDAC2
SCHEMBL89601 0.82 GRIN2D (0.39) TSHRL3MBTL1KDM4ELMNAHDAC3
SCHEMBL10282917 0.82 GRIN2D (0.41) TSHRL3MBTL1HDAC3HDAC1HDAC2
SCHEMBL8262797 0.80 GRIN2D (0.38) TSHRL3MBTL1HDAC3HDAC1HDAC2
SCHEMBL8263905 0.80 HDAC1 (0.38) ALDH1A1L3MBTL1KDM4EHDAC3HDAC1
SCHEMBL1073010 0.72 ALDH1A1 (0.61) ALDH1A1TSHRL3MBTL1KDM4ELMNA
SCHEMBL13166745 0.70 HDAC1 (0.45) ALDH1A1L3MBTL1KDM4ELMNAHDAC3
SCHEMBL57079 0.70 ALDH1A1 (0.86) ALDH1A1TSHRL3MBTL1KDM4ELMNA
SCHEMBL30146872 0.70 HDAC3 (0.53) L3MBTL1HDAC3HDAC1HDAC2NCOR2
SCHEMBL1800104 0.69 HDAC1 (0.44) HDAC3HDAC1HDAC2NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20100029647-A1 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES NOVARTIS AG (CH) 2010-02-04 US disclosed
US-20100029647-A1 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES NOVARTIS AG (CH) 2010-02-04 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
WO-2006074924-A1 3,4,(5)-SUBSTITUTED TETRAHVDROPYRIDINES NOVARTIS AG (CH) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029647-A1 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES REN, PAH, ACE ALDH1A1 412/4885TSHR 1391/4885L3MBTL1 4109/4885
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 ALDH1A1 38/4885TSHR 1095/4885L3MBTL1 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.